EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials

Claudio Ricci, Laura Alberici, Vincenzo D'Ambra, Carlo Ingaldi, Marco Fichera, Riccardo Casadei

HPB · 2026

DOI: 10.1016/j.hpb.2025.10.014 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift HPB, 2026. Verfasst von Claudio Ricci und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy. Electronic address: claudio.ricci6@unibo.it. Hauptthemen laut MEDLINE: Pancreaticoduodenectomy, Pancreatic Neoplasms, Robotic Surgical Procedures, Laparoscopy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The cost-effectiveness of a laparoscopic (LPD) and robotic pancreaticoduodenectomy (RPD), compared with the open approach (OPD), is still under debate. METHODS: A Markov decision model was developed to compare OPD, LPD, and RPD. The healthcare costs and quality-adjusted life years (QALYs) were estimated by calculating the incremental cost-effectiveness ratio (ICER) per QALY gained. A willingness-to-pay (WTP) of $130,049 was assumed as the threshold. A probabilistic sensitivity analysis (PSA) was performed to reflect the uncertainty of various parameters. RESULTS: In the base case scenario, LPD and RPD were associated with increased costs of US $30,047 and US $30,822, respectively, leading to an ICER of US $-3,911,669 and US $-1,164,992 per QALY. When comparing LPD with OPD, three main factors influence the model: OPD costs (68.8 %), LPD costs (27.9 %), and the complication rate after LPD (2.3 %). In comparing RPD with OPD, two main factors affect the model: RPD costs (75.2 %) and OPD costs (23.3 %). PSA analysis confirmed that OPD was the most cost-effective choice in most cases (62.6 %), while RPD and LPD were the most cost-effective procedures in 26.2 % and 11.9 %, respectively. CONCLUSION: The RDP and LPD were not cost-effective. OPD remained the best approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PancreaticoduodenectomyPancreatic NeoplasmsRobotic Surgical ProceduresLaparoscopyCarcinoma, Pancreatic DuctalHumansCost-Benefit AnalysisQuality-Adjusted Life YearsMarkov ChainsRandomized Controlled Trials as TopicModels, EconomicTreatment OutcomeHealth Care CostsDecision Support TechniquesMaleCost-Effectiveness Analysis

Autor:innen und Institutionen

  • Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy. Electronic address: claudio.ricci6@unibo.it.
  • Division of Pancreatic Surgery, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15- Italia, Italy.
  • Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy.
  • Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy; Division of Pancreatic Surgery, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15- Italia, Ital…

Zitieren

APA

Ricci, C., Alberici, L., D'Ambra, V., Ingaldi, C., Fichera, M., & Casadei, R. (2026). The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials. HPB. https://doi.org/10.1016/j.hpb.2025.10.014

Vancouver

Ricci C, Alberici L, D'Ambra V, Ingaldi C, Fichera M, Casadei R. The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials. HPB. 2026. doi:10.1016/j.hpb.2025.10.014

BibTeX
@article{Ricci2026,
  author = {Ricci, Claudio and Alberici, Laura and D'Ambra, Vincenzo and Ingaldi, Carlo and Fichera, Marco and Casadei, Riccardo},
  title = {The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials},
  journal = {HPB},
  year = {2026},
  doi = {10.1016/j.hpb.2025.10.014}
}
Kostenlos starten →